A quantitative mass spectrometry-based approach showed that the urinary glycoprotein, prostatic acid phosphatase (ACPP), has discrimination power for distinguishing aggressive PCa from non-aggressive PCa [201]. The gene discussed is ACP3; the disease is posterior cortical atrophy.